Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2011 Apr 12;19(4):435-7. doi: 10.1016/j.ccr.2011.03.019.

Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia.

Author information

  • 1Division of Tumour Biology, The Institute of Cancer Research, London, UK.

Abstract

ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL(T315I) mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that "switch-control" inhibitors block BCR-ABL(T315I) activity by preventing ABL from switching from the inactive to active conformation.

Copyright © 2011 Elsevier Inc. All rights reserved.

Comment on

PMID:
21481785
[PubMed]
Free full text

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk